Global Sustained Release Excipients Market Analysis & Forecast Report 2015-2018 & 2026: Increasing Focus on Novel Drug Delivery R&D and Rising Adoption of Extended Release Formulations

Dublin, Nov. 16, 2018 (GLOBE NEWSWIRE) -- The "Sustained Release Excipients Market Size, Share & Trends Analysis Report By Product (Polymers, Gelatin), By Route of Administration (Oral, Transdermal), By Technology (Targeted Delivery), And Segment Forecasts, 2018 - 2026" report has been added to ResearchAndMarkets.com's offering.

The global sustained release excipients market size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during the forecast period.

Increasing focus on novel drug delivery R&D and rising adoption of extended release formulations for treatment of chronic diseases are major factors driving the market.

Use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. In comparison to conventional drugs, sustained drug release technologies provide a wide range of benefits. Reduced dosage frequency, improved patient compliance, maintenance of constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness in the long run are some of the major advantages of using this technology.

Global rise in incidence of chronic and infectious diseases has also resulted in antibiotic resistance, which negatively affects the market for conventional dosage forms. Thus, alternative methods to manage and treat these diseases are being implemented. Use of sustained release formulations has been widely accepted among physicians in order to combat antibiotic resistance. Since these formulations create desired therapeutic drug levels in blood plasma and reduce dosage frequency, they are the preferred choice of formulation among physicians, which increases their demand.

Further key findings from the report suggest:

  • Polymers formed the largest revenue grossing segment by product type in 2017 and is anticipated to grow at a lucrative rate during the forecast period. This is due to its high adoption in sustained release formulations as they provide greater strength and improved shelf-life
  • In terms of route of administration, the oral segment held the dominant share in 2017 and is projected to witness steady growth to retain its lead throughout the forecast period
  • Transdermal technology is expected to exhibit the highest CAGR during the forecast period owing to its escalating usage. It minimizes various limitations associated with oral and parenteral route of administrations
  • North America dominated the overall market in 2017 due to well-developed research infrastructure and presence of leading pharmaceutical and biopharmaceutical companies
  • Asia Pacific is spearheading revenue growth, with Japan, China, and India at the forefront
  • Some of the key companies in the market are Coating Place, Inc.; Depomed, Inc.; Corium International, Inc.; Capsugel; Aradigm Corporation; Orbis Biosciences, Inc.; and Alkermes plc.

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Research Methodology
2.1 Country-wise Market: Base Estimates
2.2 Global Market: CAGR Calculation
2.3 Region-based Segment Share Calculation
2.4 Research Scope & Assumptions
2.5 List of Data Sources
2.6 Market Snapshot

Chapter 3 Sustained Release Excipients Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increased benefits over conventional dosage forms
3.2.2 Antibiotic resistance
3.2.3 Necessity of pediatric and geriatric sustained release dosage forms
3.2.4 Increased acceptance due to nature of dosage forms
3.3 Market Restraint Analysis
3.3.1 Drug toxicity due to dose dumping
3.3.2 Need for high dose of API
3.4 Market Challenge Analysis
3.4.1 Patient education and counselling
3.4.2 Higher cost of sustained release systems in comparison to conventional pharmaceutical formulations
3.5 Market Opportunity Analysis
3.5.1 Development cost-efficient dosage forms
3.5.2 Minimization of hepatic first pass elimination
3.6 Market Opportunity Analysis
3.6.1 Key opportunities prioritized, by product
3.6.2 Key opportunities prioritized, by route of administration
3.6.3 Key opportunities prioritized, by technology
3.7 Sustained Release Excipients - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.8 Industry Analysis - Porter's
3.9 Major Excipients Used in Sustained Release Formulations

Chapter 4 Sustained Release Excipients Market: Product Estimates & Trend Analysis
4.1 Sustained Release Excipients Market: Product Movement Analysis
4.2 Gelatin
4.3 Polymers
4.4 Minerals
4.5 Sugars
4.6 Alcohol
4.7 Chitosan

Chapter 5 Sustained Release Excipients Market: Route of Administration Estimates & Trend Analysis
5.1 Sustained release excipients market: Route of administration movement analysis
5.2 Oral
5.3 Intramuscular
5.4 Subcutaneous
5.5 Transdermal
5.6 Vaginal
5.7 Ophthalmic
5.8 Intravenous
5.9 Others

Chapter 6 Sustained Release Excipients Market: Technology Estimates & Trend Analysis
6.1 Sustained release excipients market: Technology movement analysis
6.2 Targeted Delivery
6.3 Microencapsulation
6.4 Wurster Technique
6.5 Transdermal
6.6 Implants
6.7 Coacervation
6.8 Others

Chapter 7 Sustained Release Excipients Market: Regional Estimates & Trend Analysis, by Product, Route of Administration, and Technology

Chapter 8 Competitive Landscape: Sustained Release Drugs
8.1 Teva Pharmaceutical Industries Ltd.
8.2 Mylan N.V.
8.3 Valeant Pharmaceuticals International, Inc.
8.4 Pfizer, Inc.
8.5 Sun Pharmaceutical Industries Ltd.
8.6 Novartis AG
8.7 AstraZeneca
8.8 GlaxoSmithKline plc
8.9 Allergan plc
8.10 Janssen Pharmaceuticals, Inc.
8.11 Mayne Pharma Group Limited

Chapter 9 Competitive Landscape: Sustained Release Technology
9.1 Depomed, Inc.
9.2 Coating Place, Inc.
9.3 Corium International, Inc.
9.4 Orbis Biosciences, Inc.
9.5 Capsugel
9.6 Aradigm Corporation
9.7 Alkermes plc

Chapter 10 Product Pipeline Analysis
10.1 Pipeline Development and Clinical Trials
10.1.1 Clinical Trials in Phase 4

For more information about this report visit https://www.researchandmarkets.com/research/tgcgpz/global_sustained?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceutical Intermediates

Global Sustained Release Excipients Market Analysis & Forecast Report 2015-2018 & 2026: Increasing Focus on Novel Drug Delivery R&D and Rising Adoption of Extended Release Formulations

Dublin, Nov. 16, 2018 (GLOBE NEWSWIRE) -- The "Sustained Release Excipients Market Size, Share & Trends Analysis Report By Product (Polymers, Gelatin), By Route of Administration (Oral, Transdermal), By Technology (Targeted Delivery), And Segment Forecasts, 2018 - 2026" report has been added to ResearchAndMarkets.com's offering.

The global sustained release excipients market size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during the forecast period.

Increasing focus on novel drug delivery R&D and rising adoption of extended release formulations for treatment of chronic diseases are major factors driving the market.

Use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. In comparison to conventional drugs, sustained drug release technologies provide a wide range of benefits. Reduced dosage frequency, improved patient compliance, maintenance of constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness in the long run are some of the major advantages of using this technology.

Global rise in incidence of chronic and infectious diseases has also resulted in antibiotic resistance, which negatively affects the market for conventional dosage forms. Thus, alternative methods to manage and treat these diseases are being implemented. Use of sustained release formulations has been widely accepted among physicians in order to combat antibiotic resistance. Since these formulations create desired therapeutic drug levels in blood plasma and reduce dosage frequency, they are the preferred choice of formulation among physicians, which increases their demand.

Further key findings from the report suggest:

  • Polymers formed the largest revenue grossing segment by product type in 2017 and is anticipated to grow at a lucrative rate during the forecast period. This is due to its high adoption in sustained release formulations as they provide greater strength and improved shelf-life
  • In terms of route of administration, the oral segment held the dominant share in 2017 and is projected to witness steady growth to retain its lead throughout the forecast period
  • Transdermal technology is expected to exhibit the highest CAGR during the forecast period owing to its escalating usage. It minimizes various limitations associated with oral and parenteral route of administrations
  • North America dominated the overall market in 2017 due to well-developed research infrastructure and presence of leading pharmaceutical and biopharmaceutical companies
  • Asia Pacific is spearheading revenue growth, with Japan, China, and India at the forefront
  • Some of the key companies in the market are Coating Place, Inc.; Depomed, Inc.; Corium International, Inc.; Capsugel; Aradigm Corporation; Orbis Biosciences, Inc.; and Alkermes plc.

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Research Methodology
2.1 Country-wise Market: Base Estimates
2.2 Global Market: CAGR Calculation
2.3 Region-based Segment Share Calculation
2.4 Research Scope & Assumptions
2.5 List of Data Sources
2.6 Market Snapshot

Chapter 3 Sustained Release Excipients Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increased benefits over conventional dosage forms
3.2.2 Antibiotic resistance
3.2.3 Necessity of pediatric and geriatric sustained release dosage forms
3.2.4 Increased acceptance due to nature of dosage forms
3.3 Market Restraint Analysis
3.3.1 Drug toxicity due to dose dumping
3.3.2 Need for high dose of API
3.4 Market Challenge Analysis
3.4.1 Patient education and counselling
3.4.2 Higher cost of sustained release systems in comparison to conventional pharmaceutical formulations
3.5 Market Opportunity Analysis
3.5.1 Development cost-efficient dosage forms
3.5.2 Minimization of hepatic first pass elimination
3.6 Market Opportunity Analysis
3.6.1 Key opportunities prioritized, by product
3.6.2 Key opportunities prioritized, by route of administration
3.6.3 Key opportunities prioritized, by technology
3.7 Sustained Release Excipients - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.8 Industry Analysis - Porter's
3.9 Major Excipients Used in Sustained Release Formulations

Chapter 4 Sustained Release Excipients Market: Product Estimates & Trend Analysis
4.1 Sustained Release Excipients Market: Product Movement Analysis
4.2 Gelatin
4.3 Polymers
4.4 Minerals
4.5 Sugars
4.6 Alcohol
4.7 Chitosan

Chapter 5 Sustained Release Excipients Market: Route of Administration Estimates & Trend Analysis
5.1 Sustained release excipients market: Route of administration movement analysis
5.2 Oral
5.3 Intramuscular
5.4 Subcutaneous
5.5 Transdermal
5.6 Vaginal
5.7 Ophthalmic
5.8 Intravenous
5.9 Others

Chapter 6 Sustained Release Excipients Market: Technology Estimates & Trend Analysis
6.1 Sustained release excipients market: Technology movement analysis
6.2 Targeted Delivery
6.3 Microencapsulation
6.4 Wurster Technique
6.5 Transdermal
6.6 Implants
6.7 Coacervation
6.8 Others

Chapter 7 Sustained Release Excipients Market: Regional Estimates & Trend Analysis, by Product, Route of Administration, and Technology

Chapter 8 Competitive Landscape: Sustained Release Drugs
8.1 Teva Pharmaceutical Industries Ltd.
8.2 Mylan N.V.
8.3 Valeant Pharmaceuticals International, Inc.
8.4 Pfizer, Inc.
8.5 Sun Pharmaceutical Industries Ltd.
8.6 Novartis AG
8.7 AstraZeneca
8.8 GlaxoSmithKline plc
8.9 Allergan plc
8.10 Janssen Pharmaceuticals, Inc.
8.11 Mayne Pharma Group Limited

Chapter 9 Competitive Landscape: Sustained Release Technology
9.1 Depomed, Inc.
9.2 Coating Place, Inc.
9.3 Corium International, Inc.
9.4 Orbis Biosciences, Inc.
9.5 Capsugel
9.6 Aradigm Corporation
9.7 Alkermes plc

Chapter 10 Product Pipeline Analysis
10.1 Pipeline Development and Clinical Trials
10.1.1 Clinical Trials in Phase 4

For more information about this report visit https://www.researchandmarkets.com/research/tgcgpz/global_sustained?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceutical Intermediates

Ads